Isofol Medical AB (publ)

DB:5IU Stock Report

Market Cap: €21.0m

Isofol Medical Management

Management criteria checks 1/4

Isofol Medical's CEO is Petter Lindqvist, appointed in Jan 2024, has a tenure of 1.33 years. total yearly compensation is SEK2.77M, comprised of 60.4% salary and 39.6% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth €8.51K. The average tenure of the management team and the board of directors is 1.3 years and 1.3 years respectively.

Key information

Petter Lindqvist

Chief executive officer

SEK 2.8m

Total compensation

CEO salary percentage60.39%
CEO tenure1.3yrs
CEO ownership0.04%
Management average tenure1.3yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Petter Lindqvist's remuneration changed compared to Isofol Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024SEK 3mSEK 2m

-SEK 43m

Compensation vs Market: Petter's total compensation ($USD283.37K) is below average for companies of similar size in the German market ($USD491.43K).

Compensation vs Earnings: Insufficient data to compare Petter's compensation with company performance.

CEO

Petter Lindqvist

1.3yrs

Tenure

SEK 2,767,000

Compensation

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He served as Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Ham...

Leadership Team

NamePositionTenureCompensationOwnership
Petter Lindqvist
Chief Executive Officer1.3yrsSEK 2.77m0.040%
€ 8.5k
Roger Tell
Chief Medical Officer1.3yrsSEK 67.00kno data
Margareta Hagman
Chief Financial Officerless than a yearno data0.025%
€ 5.2k

1.3yrs

Average Tenure

Experienced Management: 5IU's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jan-Eric Österlund
Independent Chairman1.3yrsSEK 773.00k0.40%
€ 83.4k
Sten Nilsson
Independent Director1.3yrsSEK 247.00k0.0019%
€ 404.1
Lars Lind
Independent Director1.3yrsSEK 421.00k0.25%
€ 53.1k
Heinz-Josef Lenz
Member of Advisory Boardless than a yearno datano data
Alain Herrera
Independent Director1.3yrsSEK 319.00kno data
Sebastian Stintzing
Member of Advisory Boardless than a yearno datano data
Helena Taflin
Independent Director1.3yrsSEK 247.00k0.15%
€ 32.6k
Takayuki Yoshino
Member of Advisory Boardless than a yearno datano data

1.3yrs

Average Tenure

75yo

Average Age

Experienced Board: 5IU's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/14 14:23
End of Day Share Price 2025/05/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Isofol Medical AB (publ) is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Ole-Andreas KrohnDNB Markets
David MartinssonDNB Markets